Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A. Ricks.
Lilly’s core activities center on discovery and development of small-molecule and biologic therapies across multiple therapeutic areas, including diabetes and metabolic disease, oncology, neuroscience, immunology and pain. Its commercial portfolio includes longstanding and well-known medicines as well as newer specialty products; examples of medicines associated with the company include Humalog (insulin), duloxetine (Cymbalta), fluoxetine (Prozac), the GLP-1/GIP receptor-directed agent tirzepatide (marketed for type 2 diabetes) and a range of oncology and migraine treatments such as Alimta, Verzenio and Emgality. The company combines internal discovery programs with external collaborations and licensing arrangements to broaden its pipeline and commercial reach.
Research and development is a central focus for Lilly, with substantial investment in clinical development, regulatory activities and manufacturing scale-up to move novel candidates from laboratory to clinic. The company operates multiple research centers and manufacturing facilities and emphasizes biopharma capabilities, including biologics and antibody-based therapies. Its pipeline spans early-stage discovery through late-stage clinical trials, targeting both established and emerging disease areas.
Strategically, Eli Lilly emphasizes innovation in chronic and complex diseases, expanding patient access to new treatments and pursuing global commercialization. The company’s operations combine proprietary R&D, manufacturing infrastructure and global commercial teams to deliver therapies to healthcare providers and patients, while also engaging in partnerships and licensing to accelerate development and distribution.